Rep. Gilbert Ray Cisneros, Jr. recently sold Pfizer shares worth up to $50,000, marking another shake-up in his financial ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President Donald Trump’s trade ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Pfizer Inc (NYSE:PFE) shares are moving lower Wednesday alongside several pharmaceutical giants after President Donald Trump ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...

Pfizer's stock has nosedived over 63% since its post-pandemic peak, scaring off investors like it's contagious. Despite the ...

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (NYSE:PFE) from Buy to Neutral.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Potato maker Lamb Weston Holdings Inc., telecom giant Verizon Communications Inc., and retailer TJX Cos. all bucked a sharp market selloff Thursday, as Wall Street turned to stocks offering exposure ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Pfizer offers a substantial 6.7% dividend yield ... This consistency matters tremendously in my investment approach. The stock's dramatic 47% decline from its three-year high has created what ...